BioNTech SE (BNTX) Free Cash Flow (2018 - 2025)
BioNTech SE (BNTX) posted Free Cash Flow of $433.8 million for Q4 2025, down 54.56% sequentially from $954.7 million in Q3 2025, and up 202.34% YoY from $143.5 million in Q4 2024.
BioNTech SE (BNTX) Free Cash Flow (2018 - 2025) Analysis & Trends
BioNTech SE has reported Free Cash Flow for 8 years, with the latest figure at $433.8 million in Q4 2025.
- Quarterly Free Cash Flow rose 202.34% year-over-year to $433.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $815.2 million (up 56.49% YoY) and the FY2025 annual result came in at $317.4 million, up 476.89% from the prior year.
- Free Cash Flow retreated to $433.8 million in Q4 2025 per BNTX's latest filing, from $954.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $4.9 billion in Q3 2022 and troughed at -$769.8 million in Q1 2025.
- A 5-year average of $1.2 billion and a median of $687.4 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow soared 1144001575.84% in 2022, then tumbled 173.79% in 2025.
- Over 5 years, Free Cash Flow stood at $273.3 million in 2021, then soared by 260.55% to $985.4 million in 2022, then rose by 2.06% to $1.0 billion in 2023, then plunged by 142.15% to -$423.9 million in 2024, then jumped by 202.34% to $433.8 million in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered $433.8 million, $954.7 million, and $196.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | -268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 433.84 Mn |
| Dec 31, 2025 | 433.84 Mn |
| Sep 30, 2025 | 954.65 Mn |
| Sep 30, 2025 | 954.65 Mn |
| Jun 30, 2025 | 196.51 Mn |
| Jun 30, 2025 | 196.51 Mn |
| Mar 31, 2025 | -769.77 Mn |
| Mar 31, 2025 | -769.77 Mn |
| Dec 31, 2024 | -423.91 Mn |
| Dec 31, 2024 | -423.91 Mn |
| Sep 30, 2024 | -621.70 Mn |
| Sep 30, 2024 | -621.70 Mn |
| Jun 30, 2024 | 1.85 Bn |
| Jun 30, 2024 | 1.85 Bn |
| Mar 31, 2024 | -281.15 Mn |
| Mar 31, 2024 | -281.15 Mn |
| Dec 31, 2023 | 1.01 Bn |
| Dec 31, 2023 | 1.01 Bn |
| Sep 30, 2023 | 940.98 Mn |
| Sep 30, 2023 | 940.98 Mn |